Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2016

01-04-2016 | Letter

Electrical atrial vulnerability and renal complications in type 2 diabetes

Authors: David Montaigne, Augustin Coisne, Philippe Sosner, Dominique Lacroix, Samy Hadjadj

Published in: Diabetologia | Issue 4/2016

Login to get access

Excerpt

To the Editor: We read with interest the recently published article by Zethelius and colleagues in Diabetologia, which studied characteristics of type 2 diabetes patients contributing to atrial fibrillation (AF) risk in a very large observational cohort [1]. The modifiable risk factor, albuminuria, was found to be strongly associated with AF in type 2 diabetes. Zethelius et al claim that microalbuminuria and macroalbuminuria, as risk factors for AF in diabetes, have not been described previously in the literature; this is incorrect, in our opinion. …
Literature
1.
Zethelius B, Gudbjörnsdottir S, Eliasson B, Eeg-Olofsson K, Svensson AM, Cederholm J (2015) Risk factors for atrial fibrillation in type 2 diabetes: report from the Swedish National Diabetes Register (NDR). Diabetologia 58:2259–2268CrossRefPubMed
2.
Nichols GA, Reinier K, Chugh SS (2009) Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 32:1851–1856CrossRefPubMedPubMedCentral
3.
Magnani JW, Williamson MA, Ellinor PT, Monahan KM, Benjamin EJ (2009) P wave indices: current status and future directions in epidemiology, clinical, and research applications. Circ Arrhythm Electrophysiol 2:72–79CrossRefPubMedPubMedCentral
4.
Alonso A, Lopez FL, Matsushita K et al (2011) Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123:2946–2953CrossRefPubMedPubMedCentral
5.
Böhm M, Thoenes M, Neuberger HR et al (2009) Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. Eur Heart J 30:1364–1371CrossRefPubMed
6.
Du X, Ninomiya T, de Galan B et al (2009) Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 30:1128–1135CrossRefPubMed
7.
Montaigne D, Bailloeuil O, Hulin-Delmotte C et al (2012) DIAB2NEPHROGENE and SURDIAGENE study groups. Renal complications correlate with electrical atrial vulnerability hallmarks in type 2 diabetic patients. Int J Cardiol 159:63–66CrossRefPubMed
Metadata
Title
Electrical atrial vulnerability and renal complications in type 2 diabetes
Authors
David Montaigne
Augustin Coisne
Philippe Sosner
Dominique Lacroix
Samy Hadjadj
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3840-0

Other articles of this Issue 4/2016

Diabetologia 4/2016 Go to the issue

Article

Stress resilience and subsequent risk of type 2 diabetes in 1.5 million young men

Article

Metabolomics uncovers the role of adipose tissue PDXK in adipogenesis and systemic insulin sensitivity

Article

Adipose tissue transcriptomics and epigenomics in low birthweight men and controls: role of high-fat overfeeding

Mini-Review

Multiple benefits of targeting inflammation in the treatment of type 2 diabetes

Letter

Pancreatic ductal hyperplasia/dysplasia with obstructive chronic pancreatitis: an association with reduced pancreatic weight in type 1 diabetes

Letter

Electrical atrial vulnerability and renal complications in type 2 diabetes. Reply to Montaigne D, Coisne A, Sosner P et al [letter]
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits